Biotech Startups

Actym Therapeutics engineers bacteria as a delivery system for therapeutics targeting cancer and fibrotic disease. Its approach uses engineered S. Typhimurium to systemically administer and locally produce multiple therapeutic payloads at the disease site to reduce systemic toxicity.

1 investor

AcuamarkDx is a molecular diagnostics company developing early cancer detection technology using proprietary qPCR and machine learning-driven assays for cancer screening and recurrence monitoring. It aims to make frequent, recurring cancer signal monitoring a standard part of primary care.

1 investor

Kubota Vision develops pharmaceutical drugs and medical devices to preserve and restore vision for patients with eye diseases worldwide. The company is a subsidiary of Kubota Pharmaceutical and focuses on treating blindness.

1 investor

1 investor

1 investor

Acurion Health develops OncoGaze, a technology that predicts clinically actionable genomic biomarkers from routine digital histology tissue slides at the biopsy stage. It serves oncologists by identifying morphological patterns in tissue images to speed up biomarker screening and guide precision cancer therapy.

1 investor

Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics targeting bacterial infections classified as priority pathogens by the WHO, CDC, and FDA. It is a publicly held company focused on antibiotic drug development.

1 investor

ACVC Partners is a venture capital firm that partners with leading corporations to invest in deep technology startups. The firm combines corporate partner expertise and resources with its own investment capabilities to support early-stage technology companies.

1 investor

ACX develops bioengineered solutions for pest control in agriculture, replacing synthetic chemicals with precision biocides. The company serves crop producers and aims to enhance food security while reducing chemical dependence and promoting biodiversity.

1 investor

Adalid Sciences engineers lipid nanoparticles to improve the delivery and efficacy of gene therapies, targeting better therapeutic outcomes with reduced side effects. The company serves developers of nucleic acid medicines and therapeutic partners seeking advanced drug delivery solutions.

1 investor

AdAlta is a clinical-stage biotechnology company developing cell and protein therapeutics for serious diseases, including cellular immunotherapies for solid cancers. It applies an "East to West" strategy combining Asian innovation in T cell therapy with Australia's clinical and manufacturing ecosystem, and has developed candidates using its proprietary i-body technology.

1 investor

Adaptam Therapeutics develops antibody-based cancer immunotherapies, including antibody-drug conjugates and bispecific antibodies, that target the immunosuppressive myeloid tumor microenvironment via novel targets such as glycan-binding proteins and Siglecs. A spin-off from CIC bioGUNE, the company serves oncology patients and is developing first-in-class therapies for multiple cancer indications.

1 investor

Adaptilens develops a biomimetic accommodating intraocular lens (A-IOL) for cataract and vision correction, an ophthalmic medical device. The company's work centers on IOL research, development, and clinical studies.

1 investor

Adare Pharma Solutions is a CDMO (contract development and manufacturing organization) and pharma services provider serving the biopharma industry with manufacturing, research and development, and patient support capabilities.

1 investor

1 investor

Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs. The company translates scientific innovation into clinically differentiated medicines for patients with advanced solid tumors and other cancer types.

1 investor

AdcoTx is a University of Cambridge spin-out developing cancer therapies, including personalized treatments, immunotherapies, cell and gene therapies, and targeted drug delivery systems. The company is linked to the MRC Laboratory of Molecular Biology in Cambridge, UK.

1 investor

Adenocyte develops LINFU (Low Intensity Non-Focused Ultrasound), a minimally invasive ultrasound technology for routine screening of the pancreas to detect pancreatic dysplasia and early-stage pancreatic cancer. The company serves clinical cancer screening for elevated- and average-risk patients, with laboratories in Haifa and Jerusalem and clinical development at the Technion and North American screening centers.

1 investor

Adeptrix develops the exoBAMS platform, using antibody-based immunoaffinity capture of extracellular vesicles combined with MALDI mass spectrometry to profile proteins, lipids, metabolites and other molecules from a single blood sample. It provides custom assay development and bioanalytical services to researchers for biomarker discovery, disease-signature analysis, and translational research in oncology, neurology, and other disease areas.

1 investor

Adesis provides contract chemistry services, including custom synthesis and process development for complex molecules, high-purity monomers, deuterated compounds, peptides, oligonucleotides, and custom linkers. It serves pharmaceutical, medical device, and specialty research programs, with production facilities in the US and Ireland.

1 investor

The page lists investment focus areas spanning life sciences, data sciences, and green technology, including therapeutic platforms, medical devices, diagnostics, AI/ML analytics, fintech, clean energy, battery tech, and advanced materials. It appears to be a venture capital firm's site presenting its sectors of interest rather than an operating company with its own products.

1 investor

ADL BioPharma, now operating as Wacker León S.L.U., offers contract development and manufacturing (CDMO) services for biotechnology processes, including fermentation and purification pilot plants, industrial-scale manufacturing, and production of beta-lactam antibiotic active ingredients and sterile APIs under GMP standards. It serves SMEs and large companies across markets such as food ingredients, flavors and fragrances, personal care, cosmetics, and pharmaceuticals.

1 investor

ADMA Biologics is a vertically integrated manufacturer that develops and commercializes plasma-derived biologic therapies for immune-compromised patients, and operates plasma collection centers. The company markets immunoglobulin products and is a publicly traded US biopharmaceutical company.

1 investor

Adovate is a life science company developing a pipeline of adenosine analog compounds, with research and laboratory work focused on medicinal chemistry and pharmaceutical development. It operates in the biotech and pharmaceutical industry.

1 investor